Mechanism of action of agomelatine: A novel antidepressant exploiting synergy between monoaminergic and melatonergic properties

CNS Spectrums

Volumn 19, Issue 3, 2014, Pages 207-212

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NORADRENALIN; SEROTONIN 2C RECEPTOR; GLUTAMIC ACID;

ANHEDONIA; ARTICLE; ATTENTION; AUTONOMIC NERVOUS SYSTEM; CIRCADIAN RHYTHM; COGNITION; DAYTIME SOMNOLENCE; DEPRESSION; DOPAMINE RELEASE; DOWNSTREAM PROCESSING; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EMOTION; EMOTIONAL BLUNTING; ENZYME ACTIVATION; HUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SEXUAL DYSFUNCTION; AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ATTENTION DISTURBANCE; COGNITIVE DEFECT; CORTICAL SYNCHRONIZATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EMOTIONAL DISORDER; MELATONERGIC PROPERTY; MENTAL STRESS; MONOAMINERGIC PROPERTY; NEUROTRANSMISSION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN SECRETION; RECEPTOR BLOCKING;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; DRUG SYNERGISM; PREFRONTAL CORTEX; RECEPTORS, MELATONIN; SEROTONIN ANTAGONISTS;

EID: 84902134934     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000248     Document Type: Article

References (13)

1. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.
2. De Bodinat C, Guardiola-Lemaitre B, Mocaer E. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010; 9(8): 928-942.
3. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010; 30(2): 135-144.
4. Stahl SM, Fava M, Trivedi M, et al. Agomelatine in the treatment of major depressive disorder: an 8 week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010; 71(5): 616-626.
5. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain. Neuropsychopharmacology. 2013; 38(2): 275-284.
6. Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine. World J Biol Psychiatry. 2010; 11(2): 148-153.
7. Tardito D, Milanese M, Bonifacino T, et al. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptordependent pathways. BMC Neurosci. 2010; 11: 68.
8. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007; 21(5): 461-471. (Pubitemid 47106935)
9. Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012; 32(4): 487-491.
10. Corruble E, de Bodinat C, Belaidi C, Goodwin GM; Agomelatine Study Group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-week randomized, controlled, doubleblind trial. Int J Neuropsychopharmacol. 2013; 16(10): 2219-2234.
11. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, doubleblind comparison with venlafaxine. J Clin Psychiatry. 2007; 68(11): 1723-1732. (Pubitemid 350247502)
12. Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011; 26(5): 252-262.
13. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A doubleblind comparison of sexual functioning, antidepressant efficacy and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008; 28(3): 329-333.